American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. (Fourth Edition, Text Revision) (DSM-IV-TR). APA, 2000.
Kessler, RC, Berglund, P, Demler, O, Jin, R, Merikangas, KR, Walters, EE.
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry
2005; 62: 593–602.
Fehm, L, Pelissolo, A, Furmark, T, Wittchen, H-U.
Size and burden of social phobia in Europe. Eur Neuropsychopharmacol
2005; 15: 453–62.
Baldwin, DS, Anderson, IM, Nutt, DJ, Allgulander, C, Bandelow, B, den Boer, JA, et al.
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol
2014; 28: 403–39.
National Institute for Health and Care Excellence. Social Anxiety Disorder: Recognition, Assessment and Treatment (Clinical Guideline CG159). NICE, 2013.
Furmark, T, Carlbring, P, Hedman, E, Sonnenstein, A, Clevberger, P, Bohman, B, et al.
Guided and unguided self-help for social anxiety disorder: randomised controlled trial. Br J Psychiatry
2009; 195: 440–7.
Mayo-Wilson, E, Dias, S, Mavranezouli, I, Kew, K, Clark, DM, Ades, AE, et al.
Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry
2014; 1: 368–76.
Titov, N, Andrews, G, Schwencke, G, Robinson, E, Peters, L, Spence, J.
Randomized controlled trial of Internet cognitive behavioural treatment for social phobia with and without motivational enhancement strategies. Aust NZ J Psychiatry
2010; 44: 938–45.
Berger, T, Hohl, E, Caspar, F.
Internet-based treatment for social phobia: a randomized controlled trial. J Clin Psychol
2009; 65: 1021–35.
Andersson, G, Cuijpers, P, Carlbring, P, Riper, H, Hedman, E.
Guided Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: a systematic review and meta-analysis. World Psychiatry
2014; 13: 288–95.
Bandelow, B, Reitt, M, Röver, C, Michaelis, S, Görlich, Y, Wedekind, D.
Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol
2015; 30: 183–92.
Blomhoff, S, Haug, TT, Hellström, K, Holme, I, Humble, M, Madsbu, HP, et al.
Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry
2001; 179: 23–30.
Davidson, JRT, Foa, EB, Huppert, JD, Keefe, FJ, Franklin, ME, Compton, JS, et al.
Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry
2004; 61: 1005–13.
Walkup, JT, Albano, AM, Piacentini, J, Birmaher, B, Compton, SN, Sherrill, JT, et al.
Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med
2008; 359: 2753–66.
Cuijpers, P, Sijbrandij, M, Koole, SL, Andersson, G, Beekman, AT, Reynolds, CF.
Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry
2014; 13: 56–67.
Karpova, NN, Pickenhagen, A, Lindholm, J, Tiraboschi, E, Kulesskaya, N, Ágústsdóttir, A, et al.
Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science
2011; 334: 1731–4.
Bui, E, Orr, SP, Jacoby, RJ, Keshaviah, A, LeBlanc, NJ, Milad, MR, et al.
Two weeks of pre-treatment with escitalopram facilitates extinction learning in healthy individuals. Hum Psychopharmacol Clin Exp
2013; 28: 447–56.
Brühl, AB, Delsignore, A, Komossa, K, Weidt, S.
Neuroimaging in social anxiety disorder – a meta-analytic review resulting in a new neurofunctional model. Neurosci Biobehav Rev
2014; 47: 260–80.
Phan, KL, Fitzgerald, DA, Nathan, PJ, Tancer, ME.
Association between amygdala hyperactivity to harsh faces and severity of social anxiety in generalized social phobia. Biol Psychiatry
2006; 59: 424–9.
Goldin, PR, Manber, T, Hakimi, S, Canli, T, Gross, JJ.
Neural bases of social anxiety disorder: emotional reactivity and cognitive regulation during social and physical threat. Arch Gen Psychiatry
2009; 66: 170–80.
Faria, V, Appel, L, Åhs, F, Linnman, C, Pissiota, A, Frans, Ö, et al.
Amygdala subregions tied to SSRI and placebo response in patients with social anxiety disorder. Neuropsychopharmacology
2012; 37: 2222–32.
Månsson, KNT, Carlbring, P, Frick, A, Engman, J, Olsson, C-J, Bodlund, O, et al.
Altered neural correlates of affective processing after internet-delivered cognitive behavior therapy for social anxiety disorder. Psychiatry Res Neuroimaging
2013; 214: 229–37.
Furmark, T, Tillfors, M, Marteinsdottir, I, Fischer, H, Pissiota, A, Långström, B, et al.
Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry
2002; 59: 425–33.
Phan, KL, Coccaro, EF, Angstadt, M, Kreger, KJ, Mayberg, HS, Liberzon, I, et al.
Corticolimbic brain reactivity to social signals of threat before and after sertraline treatment in generalized social phobia. Biol Psychiatry
2013; 73: 329–36.
Furmark, T, Appel, L, Michelgård, Å, Wahlstedt, K, Åhs, F, Zancan, S, et al.
Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry
2005; 58: 132–42.
Hariri, AR, Mattay, VS, Tessitore, A, Kolachana, B, Fera, F, Goldman, D, et al.
Serotonin transporter genetic variation and the response of the human amygdala. Science
2002; 297: 400–3.
Furmark, T, Tillfors, M, Everz, P, Marteinsdottir, I, Gefvert, O, Fredrikson, M.
Social phobia in the general population: prevalence and sociodemographic profile. Soc Psychiatry Psychiatr Epidemiol
1999; 34: 416–24.
Montgomery, SA, Asberg, M.
A new depression scale designed to be sensitive to change. Br J Psychiatry
1979; 134: 382–9.
Sheehan, DV, Lecrubier, Y, Sheehan, KH, Amorim, P, Janavs, J, Weiller, E, et al.
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry
1998; 59 (suppl 20): 22–33.
First, MB, Spitzer, RL, Gibbon, M, Williams, JBW.
Structured Clinical Interview for DSM-IV Axis I Disorders – Non-Patient Edition. Biometrics Research, New York State Psychiatric Institute, 1997.
Fresco, DM, Coles, ME, Heimberg, RG, Liebowitz, MR, Hami, S, Stein, MB, et al.
The Liebowitz social anxiety scale: a comparison of the psychometric properties of self-report and clinician-administered formats. Psychol Med
2001; 31: 1025–35.
Zaider, TI, Heimberg, RG, Fresco, DM, Schneier, FR, Liebowitz, MR.
Evaluation of the clinical global impression scale among individuals with social anxiety disorder. Psychol Med
2003; 33: 611–22.
Clark, DM, Wells, A.
A cognitive model of social phobia. In Social Phobia: Diagnosis, Assessment, and Treatment (eds Heimberg, RG, Liebowitz, MR, Hope, DA, Schneier, FR): 69–93. Guilford Press, 1995.
Andersson, G, Carlbring, P, Holmström, A, Sparthan, E, Furmark, T, Nilsson-Ihrfelt, E, et al.
Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial. J Consult Clin Psychol
2006; 74: 677–86.
Carlbring, P, Gunnarsdóttir, M, Hedensjö, L, Andersson, G, Ekselius, L, Furmark, T.
Treatment of social phobia: randomised trial of internet-delivered cognitive–behavioural therapy with telephone support. Br J Psychiatry
2007; 190: 123–8.
Borkovec, TD, Nau, SD.
Credibility of analogue therapy rationales. J Behav Ther Exp Psychiatry
1972; 3: 257–60.
Mattick, RP, Clarke, JC.
Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther
1998; 36: 455–70.
Beck, AT, Epstein, N, Brown, G, Steer, RA.
An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol
1988; 56: 893–7.
Frisch, MB, Cornell, J, Villanueva, M, Retzlaff, PJ.
Clinical validation of the Quality of Life Inventory. A measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess
1992; 4: 92–101.
Maldjian, JA, Laurienti, PJ, Kraft, RA, Burdette, JH.
An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage
2003; 19: 1233–9.
Lader, M, Stender, K, Bürger, V, Nil, R.
Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety
2004; 19: 241–8.
Reis, M, Cherma, MD, Carlsson, B, Bengtsson, F.
Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit
2007; 29: 758–66.
Montgomery, SA, Nil, R, Dürr-Pal, N, Loft, H, Boulenger, J-P.
A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry
2005; 66: 1270–8.
Blanco, C, Heimberg, RG, Schneier, FR, Fresco, DM, Chen, H, Turk, CL, et al.
A placebo-controlled trial of phenelzine, cognitive behavioral group therapy and their combination for social anxiety disorder. Arch Gen Psychiatry
2010; 67: 286–95.
Harmer, CJ, Cowen, PJ.
‘It's the way that you look at it’ – a cognitive neuropsychological account of SSRI action in depression. Philos Trans R Soc Lond B Biol Sci
2013; 368: 20120407.
Åhs, F, Pissiota, A, Michelgård, Å, Frans, Ö, Furmark, T, Appel, L, et al.
Disentangling the web of fear: amygdala reactivity and functional connectivity in spider and snake phobia. Psychiatry Res Neuroimaging
2009; 172: 103–8.
Seeley, WW, Menon, V, Schatzberg, AF, Keller, J, Glover, GH, Kenna, H, et al.
Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci Off J Soc Neurosci
2007; 27: 2349–56.